As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
How you can devise a cancer prevention action plan.
How to love yourself — and your selfies — without filters or fillers.
Treatment Study for Patients with BRAF V600E Mutation Positive Craniopharyngioma
Clinical Trial Title:
Phase II trial of BRAF/MEK inhibitors in papillary craniopharyngiomas.
Clinical Trial Protocol ID:
17110101
Clinical Trial Investigator Name:
Joo Yeon Nam, MD
Clinical Trial Protocol Description:
This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Have local diagnosis of papillary craniopharyngioma and have tissue slides available for submission to central pathology review.
- Have histologically proven papillary craniopharyngioma as documented by central pathology review with positive BRAF V600E mutation by IHC.
- Are at least 18 years of age.
This is a partial list of elgibility requirements.
Clinical Trial Area:
Brain Tumors
Contact Phone:
(312) 942-8729
Contact Name:
Praneeth Chebrolu